A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
Public ClinicalTrials.gov record NCT03846310. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).
Study identification
- NCT ID
- NCT03846310
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Interventions
- Etrumadenant Drug
- Zimberelimab Drug
- Carboplatin Drug
- Pemetrexed Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2019
- Primary completion
- Nov 17, 2024
- Completion
- Nov 17, 2024
- Last update posted
- Dec 8, 2024
2019 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Research Center (ACRC) | Tucson | Arizona | 85715 | — |
| SCRI Florida Cancer Specialists - South | Fort Myers | Florida | 33901 | — |
| SCRI Florida Cancer Specialists - North | Tavares | Florida | 33705 | — |
| SCRI Tennessee Oncology - Nashville | Nashville | Tennessee | 37203 | — |
| USO Texas Oncology - Dallas (Baylor Charles A. Sammons Cancer Center) | Dallas | Texas | 75246 | — |
| USO Virginia Cancer Specialist | Fairfax | Virginia | 22031 | — |
| USO Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Medical Oncology Associates/Summit Cancer Center | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03846310, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2024 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03846310 live on ClinicalTrials.gov.